Johnson & Johnson (NYSE:JNJ) had its price target hoisted by stock analysts at BMO Capital Markets to $161.00 in a report released on Tuesday. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 12.45% from the stock’s previous close.

Several other research analysts have also recently issued reports on JNJ. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday. J P Morgan Chase & Co increased their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group set a $145.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday, August 15th. Citigroup began coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective for the company. Finally, Royal Bank of Canada increased their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $145.04.

Johnson & Johnson (NYSE JNJ) traded up $2.04 during trading on Tuesday, hitting $143.18. 3,780,000 shares of the stock traded hands, compared to its average volume of 4,770,000. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $384,670.00, a PE ratio of 19.69, a PEG ratio of 2.86 and a beta of 0.80. Johnson & Johnson has a twelve month low of $110.76 and a twelve month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $1.68 earnings per share. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.

Several large investors have recently modified their holdings of the stock. Karpus Management Inc. purchased a new stake in Johnson & Johnson in the 3rd quarter worth approximately $231,000. Wagner Bowman Management Corp lifted its position in Johnson & Johnson by 3.2% in the 3rd quarter. Wagner Bowman Management Corp now owns 47,171 shares of the company’s stock worth $6,132,000 after buying an additional 1,452 shares in the last quarter. Hikari Tsushin Inc. lifted its position in Johnson & Johnson by 8.3% in the 3rd quarter. Hikari Tsushin Inc. now owns 53,810 shares of the company’s stock worth $6,996,000 after buying an additional 4,130 shares in the last quarter. Burgundy Asset Management Ltd. lifted its position in Johnson & Johnson by 0.4% in the 3rd quarter. Burgundy Asset Management Ltd. now owns 3,195,878 shares of the company’s stock worth $415,496,000 after buying an additional 11,257 shares in the last quarter. Finally, Chicago Partners Investment Group LLC lifted its position in Johnson & Johnson by 9.9% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 12,714 shares of the company’s stock worth $1,653,000 after buying an additional 1,144 shares in the last quarter. Institutional investors and hedge funds own 65.89% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/12/bmo-capital-markets-boosts-johnson-johnson-jnj-price-target-to-161-00.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.